This is a pilot 12-week randomized, placebo-controlled N-of-1 deprescribing trial among older
men receiving chronic tamsulosin therapy for lower urinary tract symptoms attributed to
benign prostatic hyperplasia.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)